1. Home
  2. COCP vs SNGX Comparison

COCP vs SNGX Comparison

Compare COCP & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cocrystal Pharma Inc.

COCP

Cocrystal Pharma Inc.

HOLD

Current Price

$0.98

Market Cap

15.3M

Sector

Health Care

ML Signal

HOLD

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$1.10

Market Cap

14.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COCP
SNGX
Founded
2006
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.3M
14.4M
IPO Year
2011
2006

Fundamental Metrics

Financial Performance
Metric
COCP
SNGX
Price
$0.98
$1.10
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$6.00
$6.00
AVG Volume (30 Days)
59.8K
171.5K
Earning Date
02-26-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
8.02
N/A
EPS
N/A
N/A
Revenue
$12,712,091.00
$119,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.86
$1.02
52 Week High
$2.19
$6.23

Technical Indicators

Market Signals
Indicator
COCP
SNGX
Relative Strength Index (RSI) 47.76 36.95
Support Level $0.90 $1.04
Resistance Level $0.98 $1.15
Average True Range (ATR) 0.07 0.08
MACD 0.00 -0.00
Stochastic Oscillator 55.62 25.00

Price Performance

Historical Comparison
COCP
SNGX

About COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: